Glaukos Corporation $GKOS Stock Holdings Lessened by New York State Common Retirement Fund

New York State Common Retirement Fund lessened its stake in shares of Glaukos Corporation (NYSE:GKOS) by 86.5% in the third quarter, according to its most recent filing with the SEC. The fund owned 52,174 shares of the medical instruments supplier’s stock after selling 335,727 shares during the period. New York State Common Retirement Fund’s holdings in Glaukos were worth $4,255,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. AQR Capital Management LLC raised its position in shares of Glaukos by 2.6% during the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock worth $766,000 after purchasing an additional 198 shares during the period. Jones Financial Companies Lllp increased its stake in Glaukos by 1,405.9% in the 1st quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock worth $252,000 after purchasing an additional 2,390 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Glaukos by 41.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock worth $22,636,000 after buying an additional 67,668 shares during the period. Truist Financial Corp lifted its stake in Glaukos by 138.9% during the second quarter. Truist Financial Corp now owns 7,296 shares of the medical instruments supplier’s stock valued at $754,000 after buying an additional 4,242 shares in the last quarter. Finally, KLP Kapitalforvaltning AS boosted its holdings in shares of Glaukos by 7.3% in the second quarter. KLP Kapitalforvaltning AS now owns 11,700 shares of the medical instruments supplier’s stock worth $1,208,000 after buying an additional 800 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on GKOS shares. Citigroup boosted their price target on shares of Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, December 11th. The Goldman Sachs Group reiterated a “buy” rating and set a $138.00 price objective on shares of Glaukos in a research report on Friday, January 9th. Stephens increased their target price on Glaukos from $115.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, January 2nd. Wells Fargo & Company raised their target price on Glaukos from $120.00 to $122.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. Finally, Needham & Company LLC reissued a “buy” rating and set a $125.00 price target on shares of Glaukos in a research report on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus price target of $132.54.

Insiders Place Their Bets

In other Glaukos news, CEO Thomas William Burns sold 186,945 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $115.00, for a total value of $21,498,675.00. Following the completion of the sale, the chief executive officer directly owned 153,775 shares of the company’s stock, valued at $17,684,125. The trade was a 54.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Gilbert H. Kliman sold 5,000 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $107.27, for a total transaction of $536,350.00. Following the transaction, the director owned 34,905 shares in the company, valued at approximately $3,744,259.35. This trade represents a 12.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 329,655 shares of company stock worth $37,752,234 in the last quarter. Corporate insiders own 5.80% of the company’s stock.

Glaukos Trading Down 0.9%

NYSE GKOS opened at $112.54 on Friday. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $161.78. The firm’s fifty day simple moving average is $114.34 and its 200-day simple moving average is $97.45. The company has a current ratio of 5.20, a quick ratio of 4.47 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $6.46 billion, a PE ratio of -73.08 and a beta of 0.70.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.